SOPHiA GENETICS Completes $57.5 Million Public Offering with High Demand from Investors

SOPHiA GENETICS Secures $57.5 Million Through Public Offering

In a significant financial milestone, SOPHiA GENETICS, a leader in Ai-driven precision medicine, has successfully concluded its underwritten public offering, raising a total of $57.5 million. This achievement comes as a result of overwhelming investor demand, prompting the underwriters to fully exercise their option to purchase additional shares.

The company sold a total of 12,104,900 ordinary shares, priced at $4.75 per share, reflecting a keen interest from investors seeking to capitalize on the groundbreaking advancements in healthcare technology offered by SOPHiA GENETICS. The additional 1,578,900 shares included in this offering were acquired through the underwriters' exercised option, underscoring the strong market confidence in the company's growth trajectory.

TD Cowen led the offering as the principal book-running manager, with Guggenheim Securities also playing a pivotal role as a book-running manager, while BTIG and Craig-Hallum served as lead managers. This well-coordinated effort not only facilitated the successful conclusion of the public offering but also showcased the trust and competence in managing such a large transaction.

SOPHiA GENETICS, known for its innovative Ai platform — SOPHiA DDM™, focuses on transforming patient care through data-driven medicine. By analyzing complex genomic and multimodal data, the platform generates real-time insights that can enhance decision-making processes for hospitals, laboratories, and biopharma institutions. It aims to make precision medicine more accessible to healthcare providers globally.

The registration statement for the newly issued shares was filed with the U.S. SEC and became effective in August 2025, allowing SOPHiA GENETICS to proceed with this crucial public offering following all regulatory guidelines. Investors can access the final prospectus through the SEC's website, ensuring transparency and compliance.

Despite the positive reception of the offering, SOPHiA GENETICS clarified that this announcement should not be interpreted as a solicitation for investments in jurisdictions where such activities would be deemed unlawful without proper registration. Notably, there are restrictions preventing any public offering or marketing efforts related to these securities in Switzerland due to compliance with the Swiss Financial Services Act.

This public offering not only strengthens SOPHiA GENETICS' financial position but also highlights the increasing interest in Ai-driven technologies within the healthcare sector. As the demand for innovative healthcare solutions continues to rise, SOPHiA GENETICS is poised to leverage these new funds to expand its reach and enhance its offerings, aligning with its mission to revolutionize patient care through accessible, data-informed medical practices.

In summary, SOPHiA GENETICS has not just raised capital successfully; it has also reinforced its position as a forerunner in the integration of Ai into healthcare, promising advancements that could redefine treatment methodologies and patient outcomes in the years to come.